Abstract
Objective We undertook this study to explore the role of important determinants affecting global COVID-19 incidence and mortality taking multifactorial disease dynamics into consideration.
Design Secondary data as on March 28, 2020 were obtained for 97 countries. Association of COVID-19 cumulative incidence and mortality measures were assessed with ten indictors representing health system characteristics, climate, demography, promptness of international travel restriction and population movement using Generalized Linear Modelling.
Main outcome measures Country-specific COVID-19 cumulative incidence, cumulative cause-specific mortality and case fatality rate.
Results Significant inter-country variation in incidence and mortality rates were observed. Five variables were found to be associated with cumulative incidence: testing rate per 1000 population (β = 0.119, p < 0.01), UHC index (β = 0.043, p = 0.04), percentage elderly population (β = 0.122, p < 0.01), percentage below-poverty line population (β = -0.048, p < 0.01) and disability adjusted life years due to NCDs (β = -0.013, p < 0.01). Case fatality rate was observed to be associated with testing rate per 1000 population (β = -0.058, p = 0.03) and population density (β = 0.002, p = 0.02), while the cumulative cause-specific mortality was associated with only percentage elderly population (β = 0.096, p = 0.04) in the country.
Conclusions Health system response, population susceptibility and demography were the most important factors determining the progression. Policy response should focus towards increasing testing, primarily targeting high population density areas. Health system strengthening and reduction in population risk factors should be long term goals for a better response to such epidemics.
Strengths and limitations of this study
We undertook a large scale cross-country analysis to explore the impact of background factors in a country on COVID-19 disease dynamics.
Information from 97 countries as on March 28, 2020 were retrieved from public repositories and analysed.
Generalized linear models were employed to understand percentage change in county-specific cumulative incidence, cumulative cause-specific mortality and case fatality rate with selected explanatory variables representing health system characteristics, climate, demography, policy promptness and population movement.
Our main limitation was lack of data availability in the public domain, especially on the number of COVID-19 tests conducted by many countries, which forced us to restrict our sample size to 97 countries.
We could not include a quality parameter for community based mitigation strategies, hence the effectiveness of these in reducing COVID-19 incidence and mortality could not be assessed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None of the authors received any specific funding for this study from their affiliated institutions or external funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was not required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos